Targeting CXCR1/CXCR2 Receptor Antagonism in Malignant Melanoma

Expert Opinion on Therapeutic Targets - United Kingdom
doi 10.1517/14728221003652471
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa Healthcare

Related search

CXCR2 Chemokine Receptor Antagonism Enhances DOP Opioid Receptor Function via Allosteric Regulation of the CXCR2–DOP Receptor Heterodimer

Biochemical Journal
BiochemistryCell BiologyMolecular Biology
2008English

Interleukin‑8 Promotes Cell Migration via CXCR1 and CXCR2 in Liver Cancer

Oncology Letters
Cancer ResearchOncology
2019English

CXC Chemokine Receptor 2 (CXCR2)

Science-Business eXchange
2008English

The XMRK Receptor Tyrosine Kinase Is Activated in Xiphophorus Malignant Melanoma.

EMBO Journal
ImmunologyMolecular BiologyBiochemistryMicrobiology NeuroscienceMedicineGenetics
1992English

CXCR1/CXCR2 Antagonist CXCL8(3-74)K11R/G31P Blocks Lung Inflammation in Swine Barn Dust-Instilled Mice

2011English

CCL21 Chemokine Regulates Chemokine Receptor CCR7 Bearing Malignant Melanoma Cells

Clinical Cancer Research
Cancer ResearchOncology
2004English

Hereditary Malignant Melanoma

BMJ
1967English

Familial Malignant Melanoma

Plastic and Reconstructive Surgery
Surgery
1973English

Genetic and Functional Evaluation of the Role of CXCR1 and CXCR2 in Susceptibility to Visceral Leishmaniasis in North-East India

BMC Medical Genetics
Genetics
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy